Anish Patel Sells 6,667 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction dated Wednesday, May 7th. The shares were sold at an average price of $18.39, for a total transaction of $122,606.13. Following the completion of the sale, the chief operating officer now owns 309,976 shares in the company, valued at $5,700,458.64. This represents a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Anish Patel also recently made the following trade(s):

• On Monday, April 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.04, for a total transaction of $120,272.68.
• On Friday, March 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.44, for a total transaction of $142,940.48.

Enliven Therapeutics Stock Performance

Shares of ELVN stock opened at $18.51 on Monday. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.03. The firm has a market capitalization of $908.21 million, a price-to-earnings ratio of -9.74 and a beta of 1.07. The stock’s 50-day simple moving average is $19.06 and its 200-day simple moving average is $21.99.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. As a group, equities analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ELVN. FMR LLC increased its position in shares of Enliven Therapeutics by 3.2% in the 4th quarter. FMR LLC now owns 6,495,871 shares of the company’s stock valued at $146,157,000 after acquiring an additional 199,692 shares during the period. Polar Capital Holdings Plc grew its stake in Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock valued at $53,768,000 after purchasing an additional 1,739,668 shares during the last quarter. Vanguard Group Inc. grew its stake in Enliven Therapeutics by 2.9% during the 4th quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company’s stock valued at $44,452,000 after purchasing an additional 55,283 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Enliven Therapeutics by 27.9% in the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company’s stock valued at $30,001,000 after purchasing an additional 290,153 shares during the period. Finally, Pictet Asset Management Holding SA raised its stake in shares of Enliven Therapeutics by 16.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company’s stock worth $21,877,000 after purchasing an additional 135,969 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 21st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.